VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
FLGT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
FLGTFulgent Genetics, Inc.
$21.65$615M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksFLGTCash Flow

Fulgent Genetics, Inc. (FLGT) Cash Flow Statement

12Y historyFree accessUpdated daily

Free cash flow has turned sharply negative with a margin of -32.3% in 2026Q2, and the combination of operational cash burn and a $55.6M acquisition is rapidly consuming the company's liquidity.

Income StatementBalance SheetCash FlowRatios

FLGT Cash Flow Statement

Annual statement

FLGT Cash Flow Statement

Fulgent Genetics, Inc. (FLGT) cash flow statement — 12-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14
Cash from Operations-83.7M-101.64M21.06M27M253.52M538.58M140.63M5.52M-675K1.33M4.41M-969K-4.4M
Operating CF Margin %--31.5%7.43%9.34%40.96%54.26%33.35%16.96%-3.16%7.11%24.1%-10.12%-344.05%
Operating CF Growth %40.69%-582.61%-22.01%-89.35%-52.93%282.98%2448.99%917.33%-150.71%-69.78%554.59%77.96%-
Net Income-84.38M-61.63M-43.82M-175.24M141.92M506.24M214.31M-411K-5.61M-2.51M-5.39M-4.99M-990K
Depreciation & Amortization24.19M24.12M24.93M26.14M32.66M11M2.96M2.52M2.16M1.73M1.17M575K196K
Stock-Based Compensation37.51M39.58M44.48M42.92M32.64M15.88M8.16M02.3M2.12M4.65M8.16M0
Deferred Taxes-2.45M-1.21M-5.15M7.61M831K-7.84M-1.4M-21K36K-336K246K-3.33M0
Other Non-Cash Items10.72M15.14M7.86M122.73M43.46M15.97M8.05M4.34M1.67M1.04M5.58M362K-3.28M
Working Capital Changes-68.2M-117.63M-7.24M2.84M2M-2.68M-91.45M-915K-1.24M-714K-1.86M-1.75M-323K
Change in Receivables6.69M-23.25M-16.3M2.39M68.64M42.3M-178.48M-839K-1.97M214K-2.32M-1.78M-416K
Change in Inventory00000000-36.18M-30.49M-23.45M-2.35M-331K
Change in Payables-3M550K3.07M-6.9M-25.34M-12.21M22.62M-329K102K-363K1.09M132K150K
Cash from Investing91.98M111.37M-58.35M38.9M-261.31M-546.55M-326.44M-29.05M950K-2.05M-42.8M-2.21M-780K
Capital Expenditures-20.09M-22.57M-40.31M-22.21M-18.77M-23.81M-36.51M-1.18M-2.83M-5.36M-3.79M-2.1M-731K
CapEx % of Revenue6.2%7%14.22%7.68%3.03%2.4%8.66%3.63%13.26%28.6%20.73%21.93%57.2%
Acquisitions-51.79M3.77M0-399K-182.68M-61.87M-2.59M0510K2.46M10K3.57M0
Investments-------------
Other Investing11K5K313K775K412K31K8K0-510K-2.46M10K-105K-49K
Cash from Financing-70.04M-14.79M-4.85M-47.78M-77.14M85.41M261.25M28.77M15K-770K45.79M3.5M4M
Debt Issued (Net)-828K-870K-1.77M-20M-1.07M-11K15.02M000000
Equity Issued (Net)-64.68M-13.92M-3.12M-27.79M-76.11M85.32M246.13M28.77M0051.79M00
Dividends Paid0000000000-4.59M00
Share Repurchases-64.69M-13.92M-3.12M-27.79M-76.11M-4.16M-62K-21K00000
Other Financing-4.53M051K3K31K96K104K015K-770K-1.41M3.5M4M
Net Change in Cash-61.58M-4.95M-42.19M17.97M-85.39M77.47M75.46M5.23M246K-1.41M7.4M326K-1.18M
Free Cash Flow-103.79M-124.21M-19.25M4.8M234.75M514.73M104.12M4.33M-3.51M-4.03M617K-3.07M-5.13M
FCF Margin %-32.04%-38.49%-6.79%1.66%37.93%51.86%24.69%13.33%-16.42%-21.49%3.38%-32.05%-401.25%
FCF Growth %-73.12%-545.09%-501.48%-97.96%-54.39%394.37%2301.8%223.61%12.87%-752.35%120.1%40.15%-
FCF per Share-3.71-4.04-0.640.167.5816.624.330.23-0.20-0.230.03-0.24-0.29
FCF Conversion (FCF/Net Income)1.23x1.68x-0.49x-0.16x1.77x1.06x0.66x-13.42x0.12x-0.53x-0.82x0.12x1.03x
Interest Paid100K52K512K960K000000000
Taxes Paid63.12M96.44M27.59M3.26M56.19M237.07M20.61M01K757K550K00

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetAdequate
Cash FlowDeteriorating
Top Statement Risk

Unsustainable cash burn rate

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Earnings Quality Deteriorates with Cash Burn

The relationship between net income and operating cash flow has become erratic, with the OCF/NI ratio swinging from 3.34 in 2025Q4 to 0.80 in 2026Q2, suggesting that recent losses are increasingly translating into actual cash outflows.

The volatile OCF/NI ratio indicates that non-cash adjustments like depreciation and stock-based compensation are no longer sufficient to offset the cash impact of operating losses. In 2026Q2, the $18.5M in SBC and $6.0M in D&A were overwhelmed by a $15.6M working capital outflow, resulting in operating cash burn nearly matching the net loss. This pattern suggests the quality of earnings has deteriorated, as losses are now consuming cash rather than being buffered by accruals.

Free Cash Flow Trajectory Turns Sharply Negative

FLGT's free cash flow margin has collapsed from a positive 27.9% in 2024Q4 to a deeply negative 32.3% in 2026Q2, indicating the business is now consuming significant capital relative to its revenue base.

The FCF trajectory shows a clear deterioration, with the company swinging from generating $21.2M in FCF in 2024Q4 to burning $27.6M in 2026Q2. This negative trend is driven by both operating losses and, in some quarters, elevated capital expenditures. The persistent negative FCF, especially in the most recent quarter, implies the company is not generating the cash needed to fund its operations and investments internally.

Working Capital Swings Amplify Cash Volatility

Working capital changes have been a major driver of cash flow volatility, with a $71.7M outflow in 2025Q4 followed by a $16.8M inflow in 2026Q1, suggesting inconsistent collection cycles or inventory management.

The large negative working capital change in 2025Q4 was the primary reason for the $78.1M operating cash burn that quarter, despite a smaller net loss. The subsequent positive swing in 2026Q1 provided temporary relief but did not signal a sustainable improvement. This volatility suggests potential issues with receivables collection or inventory buildup, which are creating unpredictable cash flow patterns that complicate financial planning.

Strategic Acquisition Consumes Liquidity

FLGT deployed $55.6M for an acquisition in 2026Q1, a significant use of cash that, combined with ongoing share repurchases, is depleting the company's cash reserves during a period of operational cash burn.

The $55.6M acquisition in 2026Q1 represents a major capital allocation decision made while the core business was generating minimal free cash flow. This was funded alongside $40.1M in share repurchases in the same quarter, indicating a potential misalignment between strategic investments and the company's cash generation capacity. The continued share repurchases, even as FCF turns negative, warrant scrutiny regarding capital discipline.

Cash Flow Statement Obscures True Burn Rate

The cash flow statement may understate the true economic cost of operations, as $18.5M in stock-based compensation in 2026Q2 is a non-cash expense that still represents a real dilutive cost to shareholders.

While SBC is added back to calculate operating cash flow, it is a real cost borne by existing shareholders through dilution. In 2026Q2, SBC represented over 20% of the net loss, meaning a significant portion of the 'loss' is a non-cash accounting charge. However, this does not eliminate the cash burn; it merely re-characterizes part of it. Investors should monitor the total cash burn inclusive of the dilutive impact of SBC to understand the full economic cost of the company's operations.

FLGT — Frequently Asked Questions

Quick answers to the most common questions about buying FLGT stock.

How much cash does Fulgent Genetics, Inc. (FLGT) generate from operations?

Fulgent Genetics, Inc. (FLGT) generated $-101.6M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Fulgent Genetics, Inc.'s free cash flow?

Fulgent Genetics, Inc. (FLGT) reported negative free cash flow of $124.2M in 2025, indicating capital requirements exceeded cash from operations.

What is Fulgent Genetics, Inc.'s capital expenditure (CapEx)?

Fulgent Genetics, Inc. (FLGT) spent $22.6M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Fulgent Genetics, Inc. distribute cash to shareholders?

In 2025, Fulgent Genetics, Inc. (FLGT) spent $13.9M on share repurchases. This shows the company's commitment to returning capital to its equity investors.